Polivy (polatuzumab vedotin-piiq) | Friends of Cancer Research

You are here

Polivy (polatuzumab vedotin-piiq)

Sponsor: 
Genentech, Inc.
Indication: 
Adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies
Category: 
Year: 
2017
Date: 
Dec 10th
FDA Status: 
FDA Approval
Approval Date: 
Jun 10th
Approval Year: 
2019